<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Seven patients were treated with low dose Ara-C (LDAC) </plain></SENT>
<SENT sid="1" pm="."><plain>Five patients had <z:hpo ids='HP_0011009'>acute</z:hpo> nonlymphoid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (ANLL), two patients had myelodisplastic syndrome (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>): <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA) and <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess of blasts in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t) </plain></SENT>
<SENT sid="2" pm="."><plain>Ara-C treatment was given by s.c. injections at a dose of 10-11 mg/m2 every 12 h and only on two occasions by continuous infusion </plain></SENT>
<SENT sid="3" pm="."><plain>No improvement, or limited improvement, was observed in five patients and they died of <z:hpo ids='HP_0001909'>leukemia</z:hpo> or of disease-related complications </plain></SENT>
<SENT sid="4" pm="."><plain>Two patients with ANLL achieved remission: the first patient after bone marrow <z:mpath ids='MPATH_58'>aplasia</z:mpath>, the second without <z:mpath ids='MPATH_58'>aplasia</z:mpath> but with morphologic evidence of granulocytic differentiation of leukemic cells </plain></SENT>
</text></document>